Rationale: Hypertension is a major risk factor for cerebral small vessel disease, the most prevalent cause of vascular cognitive impairment. As we have shown, hypertension induced by a prolonged Ang II infusion is associated with increased permeability of the blood-brain barrier (BBB) and chronic activation of microglia. In this study we therefore aim to determine the contribution of microglia to hypertension-induced cognitive impairment in an experimental hypertension model by a pharmacological depletion approach.
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Introduction
Cerebral small vessel disease (cSVD) is an age-related cerebral microangiopathy [1, 2] . It is expected that the prevalence of cSVD will increase in our aging society [2, 3] . cSVD is the leading cause of vascular cognitive impairment (VCI), an umbrella term that covers all cognitive disorders from mild cognitive impairment to vascular dementia [1, 4] . Hypertension is the major risk factor for the development of cSVD [2] . cSVD is associated with structural abnormalities on brain magnetic resonance imaging (MRI) including lacunes, white matter hyperintensities (WMH), cerebral microbleeds and enlarged perivascular spaces [5] . Despite a profound impact on human health, there is no specific treatment for cSVD [6, 7] , mainly due to limited understanding of the disease's pathobiology.
There is increasing evidence that blood-brain barrier (BBB) dysfunction plays a pivotal role in the pathophysiology of cSVD [8] [9] [10] [11] [12] . Under healthy conditions, the BBB functions in a well-regulated manner to ensure the provision of nutrients while protecting brain cells from blood constituents by forming a physical barrier [10, 13, 14] . The BBB is composed of vascular endothelial cells interconnected through tight junctions, flanked by pericytes, astrocytes, microglia cells and perivascular extracellular matrix. Proper interaction between its cellular and noncellular components is required to maintain a selective barrier function of the BBB [13, 14] . MRI studies have demonstrated higher BBB permeability in cSVD patients [8, 9] and this was associated with structural brain damage and cognitive impairment [8, 9, 15] . Pathological investigations have revealed the association of BBB leakages with WMH lesions and dementia [16, 17] . Leakage of plasma components into the parenchyma will elicit a local inflammatory response by Fc receptor-induced microglia activation, amongst others [18] [19] [20] . Microglia are brain resident myeloid cells which for their maintenance throughout the entire lifespan rely on their self-renewal capacity [21, 22] , orchestrated by growth factor colony stimulating factor 1 (CSF1) and its receptor (CSF1R) [23] . In order to maintain physiological conditions, microglia are critical [24] [25] [26] [27] by responding to conditions of tissue damage notably by clearing the accumulated debris [28, 29] . However, increased permeability of the BBB may lead to persistent microglia activation [30, 31] , and potentially contribute to the progression of the pathology.
The use of Angiotensin II (Ang II) infusion has been previously associated with hypertension-induced cerebrovascular dysfunction including increased BBB permeability and neuroinflammation [32] [33] [34] . We have also shown earlier the presence of activated microglia in association with BBB leakages and short-term memory impairment in a prolonged Ang II infusion (12 weeks) model [35] . We hypothesize that the depletion of microglia protects against hypertension-induced cognitive dysfunction due to the absence of microglial activation. In this present study we aim to decipher the contribution of microglia to hypertension-induced cognitive impairment via their depletion using a highly selective CSF1R inhibitor.
Material and Methods
Animals
All animal experiments were approved by the regulatory authority of Maastricht University and were performed at Maastricht University in compliance with the national and European guidelines. Cx3Cr1 GFP/GFP mice (Jackson Lab 005582) were crossed with Thy-1 YFP/0 mice (Jackson Lab 003782) to generate Cx3Cr1 GFP/WT Figure 1A ). Three animals died or were sacrificed prior to the end of the study due to haemorrhage in the thoracic cage (Ang II, vehicle), peritonitis due to a missed injection (Ang II, PLX5622) and severe weight loss after blood pressure measurement (Saline, PLX5622). Mice used for histology received an i.v. injection of 70kDa-dextran Texas Red (100 µL; 2,5 mg/mL in sterile NaCl 0,9%, D1864, Thermo Fisher), while under isoflurane anesthesia, to detect the presence of BBB leaks by histology.
The injected dextran was allowed to circulate for 3 min before mice were euthanized by exsanguination. A second series of mice was euthanized after blood collection and intra-cardiac perfusion with PBS and heparin for FACS analysis of blood and brain samples.
Cardiovascular phenotyping
Systolic BP was monitored before minipump implantation and after 5 and 10 weeks in awake mice using tailcuff plethysmography (CODA, Kent Scientific) as previously described [35] . 
Cognitive tests
Long-term spatial memory was tested in the Morris Water Maze (MWM) [36] . Shortly, the swim tank was divided into four quadrants and a platform was located in a fixed location. A video camera automatically recorded the mice movements (via a tracking system EthoVision, Noldus). Mice were subjected to the following testing schedule for MWM: spatial navigation with acquisition (days 1-4) and a probe trial (day 5). In all testing procedures the mice were given four trials per day with an inter-trial interval of 10 minutes and using four different starting positions. Each trial started with the mouse facing the wall of the pool and ended when the mouse reached the platform, or after 60 s. At day 5, a probe trial was conducted in which the platform was removed from the tank and the mouse was allowed to swim in the tank for 60 s. The swimming distance to reach the platform (cm) during test trials as well as the swimming speed and the time spent in the target quadrant during the probe trial (seconds), were obtained by Ethovision.
Short-and long-term memories were assessed in the two weeks preceding sacrifice. Short-term spatial memory was tested using an object location task (OLT) at 1 h intertrial intervals [35] . Briefly, this 2-trial task consisted of a learning (T1) trial and a test trial (T2). In T1, a set of two identical objects were placed symmetrically in the middle of a circular arena, which the mouse was allowed to explore freely for 4min. After a 1 h interval spent in their home cage, the mice were placed in the arena for T2; in this 4 min-trial, one of the objects (right or left) was moved to a different location (front or back), while all other stimuli were kept the same. Mice will spend more time exploring the moved object than the stationary object if they remember the previous location. The time spent exploring each object was scored manually on a computer by an experimenter blind to the experimental groups. Trials were excluded from the analysis when the total exploration time was inferior to 6 seconds. The discrimination index d2 assesses whether the mouse spends more time at the novel location than at the familiar location (the difference between location exploration times divided by the total exploration time). Functional spatial short-term memory is reflected by a d2 index higher than zero (both objects equally explored) [37] .
Blood and brain FACS Heparinized whole blood was used for flow cytometry using the following antibody cocktail: CD45-PerCP (Biolegend 103130), CD3-eFLUO450 (eBioscience 48-0032), NK1.1-PE (BD557391), Ly6G-APC-CY7 (BD560600), CD11b PE-CY7 (BD552850), Ly6C-APC (Miltenyi 130-093-136), CD19-APC-H7 (eBioscience 47-0193) and Siglec-F-PE (BD552126). Further, cells from the whole brain were isolated for FACS.
Anesthetized mice were perfused with PBS to remove the peripheral blood. Subsequently, brains were Quantifications of microglia, perivascular macrophages, blood brain barrier leakages, myelin integrity and neuronal loss.
All analyses were performed by a blinded investigator using ImageJ (Fiji Distribution, NIH). Microglia were counted as Cx3Cr1 + /Iba1 + cells on 6 randomly selected volumes within the neocortex (x=366; y=366; z=20 µm; n=5-6). Perivascular macrophages (PVMs) were counted as CD206 + cells [38] on 8 volumes selected to include cortical penetrating vessels within the neocortex (x=275; y= 275; z=22 µm; n=5-6). BBB permeability was assessed by determining the level of extravasation of the 70kDa-dextran probe and plasmatic IgG proteins into the brain parenchyma as shown previously [35] . Identification of IgG leakages was performed morphometrically by one investigator, who was blinded to the experimental groups. BBB leakages were defined as a signal with an intense core and diffuse borders. A series of brain slices (6 slices per brain; n=6 mice) were screened to identify and localize IgG and dextran leakages (Nikon Ti-Eclipse slide scanner). Zstack images of all identified leakages were then acquired by confocal microscopy (x= 175; y= 175; z=20 µm).
The fluorescent signal of each leakage was then analyzed in ImageJ to quantify the leakage size in mm 2 .
MBP signal in the corpus callosum, a myelin-rich area, was used to assess changes in myelin composition in the different experimental groups. Corpus callosum thickness and MBP signal intensity were measured at 3 defined locations in the lateral and medial corpus callosum (bregma level: +0.7 mm, 2 slices per brain, n=6).
The intensity of the myelin signal was examined in 8 leakages versus contralateral brain regions without leakages. Image stacks (x=550; y=550; z=30 μm) of leakages were acquired by confocal microscopy.
Chemicals
All chemicals were from Sigma-Aldrich (Zwijndrecht, The Netherlands) unless otherwise specified. PLX5622
was provided by Plexxikon Inc. and formulated in standard chow (19% protein, 5% fat, 5% fiber, 0.2%).
Statistical analyses
All statistical analyses were performed with GraphPad Prism 6 software. Data are expressed as standard error of the mean (SEM). The normality distribution was tested with the Shapiro-Wilk test. Two-way ANOVA tests were performed with Ang II and PLX5622 treatments as independent variables, followed by Tukey's or Sidak multiple comparison post-hoc tests between individual groups. A p value < 0.05 was considered as statistically significant.
Results
CSF1R inhibition and cardiovascular phenotype
PLX5622 treatment had no impact on body weight progression. Ang II infusion decreased the body weight in both control and PLX5622 groups compared to Saline infused mice (27,2±0.8 g and 29.1±0.8 g in Ang II groups vs 30.2±1.1 g and 29.7±1.1 g in Saline groups respectively at week 12; Fig. 1B , group effect pAng II < 0.05).
Systolic blood pressure was increased by Ang II at 5 weeks in both PLX5622 and vehicle treated groups and remained elevated at 10 weeks in both groups (Fig. 1C , pAng II <0.001). Heart weights, normalized to tibia lengths, as well as carotid pulsatility indices were significantly increased in the Ang II compared to Saline groups and not changed by PLX5622 treatment (Fig. 1E , pAngII <0.001 and Fig. 1F , pAngII <0.05, respectively).
CSF1R inhibition and number of microglia, perivascular macrophage number and circulating immune cells
Flow cytometry analysis of CD45 int Cx3Cr1 hi CD11b hi cells revealed effective depletion of microglia in whole brains by the CSF1R antagonist PLX5622 (-94% in Saline groups; -83% in Ang II groups; pPLX5622<0.0001) ( Fig. 2A ). This was confirmed by immunohistochemistry showing profoundly decreased density of Cx3Cr1 + Iba-1 + cells in the cerebral cortex of PLX5622 treated mice (-99% in Saline groups; -92% in Ang II groups;
pPLX5622<0.001) ( Fig. 2B ). CD206 + PVMs numbers, surrounding cortical penetrating arterioles, were reduced as well in the PLX5622 treated groups (67% in Saline groups; -56% in Ang II groups; pPLX5622<0.001) (Fig. 2C ).
Treatment with PLX5622 did not influence CD45 + cells, CD19 + B-cells and CD3 + T-cells in the blood (Fig. 3A-C ). CD45 + Cx3Cr1 + Ly6C low non-classical monocytes were reduced after 12 weeks of PLX5622 treatment (-64% in Saline group; -69% in Ang II group; pPLX5622<0.001), whereas the number of CD45 + Cx3Cr1 + Ly6C high classical monocytes did not change ( Fig. 3D-F ). 
CSF1R inhibition attenuates short-term memory impairment in hypertensive mice
Mice were first tested on the Morris water maze to evaluate learning and spatial memory [39] . There was no overall effect of PLX5622 treatment and/or Ang II infusion on the escape distance during the training trials.
The distance to reach the platform was however increased for the saline PLX5622 group vs Saline controle group but only at day 2. (Fig. 4A ). For the probe trial, swimming speed was not different between the groups, which is indicative of normal motor behaviour. Both Ang II and PLX5622 did not influence the time spent in the target quadrant ( Fig. 4B, C) . Thus, long-term memory performance during the MWM task was not affected by Ang II and/or PLX5622 treatment.
In the object location task, the total exploration times did not differ between groups, indicating again that motor behavior is normal in all animals (Fig. 4D ). Normotensive mice spent more time exploring the object at the novel location as indicated by the positive discrimination index d2 (Saline, Control: p=0.01; Saline, PLX5622:
p=0.02). PLX5622 did not affect task performance in normotensive mice. Vehicle treated Ang II-infused mice were unable to discriminate between the two objects with d2 different from the Saline group and not different from zero, i.e. chance performance (p=0.69). However, Ang II-infused mice treated with PLX5622 performed significantly better compared to untreated Ang II-infused mice, as d2 did not differ from its respective Saline group. The discrimination index d2 was however not completely back to normal as it was still not statistically different from 0. (Fig. 4E ). 
CSF1R inhibition and Ang-II induced blood-brain barrier leakage and myelin integrity
BBB permeability was assessed by the extravasation into the brain parenchyma of the 70kDa-dextran probe and plasmatic IgG proteins (Fig. 5A ). Both the total number (pAngII = 0.001; Fig. 5B ) and average size of BBB leaks, as judged from 70 kDa dextran and IgG extravasation (pAngII = 0.02 and pAngII = 0.003 respectively; Fig   5C,D) were significantly increased in the Ang II groups. Treatment with PLX5622 did not influence number or size of BBB leaks. The local decrease in microglia density at the leakage site in the PLX5622 treated groups was equivalent to the observed global depletion (pplx5622 < 0.001) and there was no effect of Ang II on the microglia density at the leakage sites (Fig. 5E ). Myelin intensity in leakage sites in the PLX5622 treated animals was not significantly different between the saline and Ang II groups (p=0.7) (Fig 6A,B) . The size of the corpus callosum ( Fig. 6C ) and the intensity (data not shown) of the myelin signal in corpus callosum was not different between the study groups. 
Discussion
An impaired BBB permeability induced by chronic hypertension is associated with microglia activation and short-term memory impairment [32] [33] [34] [35] . In the present study we aimed to determine the contribution of microglia cells to hypertension-induced cognitive impairment using a pharmacological depletion approach. Our main finding is that short-term memory impairment caused by Ang II-induced hypertension was absent after microglia / PVM depletion, in support of a critical role of microglia in the pathogenesis of VCI.
To determine the effects of microglia depletion on cognitive function, short-and long-term spatial memory were assessed in an OLT and a MWM, respectively. In the OLT, we found that hypertensive mice had impaired short-term memory, as they could not discriminate between the new and the old object location, confirming earlier work by us [35] , and others, based on similar tasks [33] . Treatment with the CSF1R inhibitor PLX5622 partly obviated the hypertension associated impairment of short-term memory without altering the normal cognitive function of control mice. In the Morris Water Maze task however, both groups of Ang-II infused mice showed a normal spatial learning and memory as observed previously [40] . The overall performance of the animals in the PLX5622 groups was also not altered, although post-hoc testing revealed an increased distance to reach the platform in the Saline PLX5622 group at day 2. It is debatable whether this statistical significant effect has any biological significance taking into account the overall lack of effect of PLX5622 on normal behavior [41] .
The observed attenuated hypertension-induced short-term memory impairment mediated by CSF-1R inhibition is a novel finding. This results aligns with findings in other brain disease models as microglia depletion by CSF1R inhibition has proven to be effective to prevent radiation induced short-term memory impairment in mice [42] and to improve the cognitive function in a mouse model of Alzheimer's disease [41] . In analogy to previous short-and long-term CSF1R inhibition studies, the overall behaviour and cognitive function of control mice were unaltered [23, [41] [42] [43] . Furthermore, dampening microglial reactivity using minocycline, was benefical for subcortical white matter functioning and cognitive performance in an animal model of chronic cerebral hypoperfusion [44, 45] , strengthening the importance of targeting microglia to limit the impact of cerebrovascular diseases.
In accordance with our prior study [35] , we found an increased BBB permeability in Ang II infused hypertensive mice, which was not altered by PLX5622 (Fig. 5 ). Increased BBB permeability causes leakage of plasma components which can induce microglia activation by binding the Fc receptors on these brain resident immune cells [18, 33, 46] . IgG leakage in the brain parenchyma is associated with an exacerbated neuroinflammatory response as shown by the increased density and soma size of microglia in different brain regions [35] .
Quantification of the microglia density around the leakage sites revealed overt depletion of microglia cells surrounding the leakage in the PLX5622 treatment groups, demonstrating that PLX5622 was also effective at the site of leakages. This suggests that the expected BBB leakage-associated neuroinflammatory response is dampened by the treatment.
Emerging evidence from animal models and clinical studies on cSVD points to a clear association between increased blood brain barrier permeability and cognitive impairment [11, 15, 30] . Our results confirm this association between BBB leakages and cognitive impairment in the untreated hypertensive group and moreover adds new knowledge by demonstrating that CSF1R targeted depletion of microglia can prevent cognitive decline in hypertensive mice despite increased BBB permeability. Although we could not associate the protective effect offered by the microglia depletion with an improvement of myelin intensity in sites of BBB leakages, we occasionally observed impaired neuronal tracts (Thy1 + ) at the site of leakages, which may account for the decline in short-term memory induced by Angiotensin II. The high variability of the locations and sizes of the BBB leakages is however not compatible with neuronal tracing of Thy1 + neurons. Furthermore, the observed beneficial effect of PLX5622 might also result from a preserved neuronal plasticity as a recent study has revealed that the downregulation of neuronal and synaptic genes in an Alzheimer'disease model was prevented in absence of microglia [47] .
Microglia depletion can be achieved by genetic deletion (Csf1r -/-Pu.1 -/mice), or by a pharmacologic depletion (CSF1R signaling inhibition) [29] . In the present study, we opted for pharmacological depletion as it is timecontrolled and applicable in any mouse strain, using the highly selective CSF1R inhibitor PLX5622 for the depletion of microglia cells. PLX5622 has proven to induce a rapid and effective microglia depletion of more than 90% after 3-7 days of treatment [41, 42, 48, 49] . Even after 3 months of PLX5622 treatment cortical Iba-1 + Cx3Cr1 + cell numbers were reduced by 90% (Fig. 2B ), a finding that was confirmed on whole brain by flow cytometry of CD45 int Cx3Cr1 hi CD11b hi cells. These data are in line with previous findings using CSF1R inhibition in several mouse models [41, 50] . While tissue macrophages and circulating monocytes express CSF1R as well, their survival is not only depending on CSF1/CSF1R signalling but relies also on CCL2/CCR2 signalling which is not present in microglia. We expected therefore that the PLX5622 treatment would lead to a mild reduction of tissue macrophages and monocyte populations [51] . Perivascular macrophages (PVMs) are brain macrophages that originate from hematopoietic precursors cells, express the mannose receptor (CD206 + ) and reside in the perivascular space of penetrating vessels [52, 53] . Activation of PVMs subsequent to BBB leakage has been shown to induce the production of ROS [38, 54] . Their depletion, using the injection of clodronate liposomes, was able to preserve both short-and long-term memory in a spontaneous hypertensive mouse model [38] . Although there was no change in PVM numbers following Ang II infusion in our study, as observed in earlier work [38] we found however a 50% reduction of the CD206 + PVM numbers due to the PLX5622 treatment. We cannot exclude that the favorable cognitive outcome in the hypertensive group after PLX5622 treatment is partly due to a reduction in the number of PVMs, although the total number of PVMs, limited to the perivascular space of large vessels, is clearly inferior to the > 2 million microglia populating a mouse brain [55] . To further investigate the effect of long-term CSF1R inhibition on circulating immune cells, we performed flow cytometry of the peripheral blood. We found a reduction of more than 50% of the non-classical Ly6C low monocytes in the PLX5622 treated groups while there was no effect of the treatment on the classical Ly6C high monocytes. Comparable results were obtained in a mouse study using PLX5622 for 7-days with a 30% reduction of the non-classical monocytes (Ly6C Low ) and no effects on the classical monocytes (Ly6C Hi ) [48] . In another study using a CSF1R antibody in cynomolgus monkeys, a decrease in non-classical CD14 + CD16 + monocytes was also observed while the classical CD14 + CD16 − monocyte population was unchanged [56] . Overall, the selective partial depletion of non-classical monocytes is in line with their low/negative CCR2 expression in comparison to classical monocytes (CCR2 high ), making them vulnerable to CSF1R inhibition. There is in the literature no evidence that non-classical monocytes are directly involved in the pathogenesis of cerebrovascular disease or that depletion of the non-classical monocytes is protective in this disease.
In addition, the depletion of microglia, and partially PVMs as achieved in our study, did not lead to a blood pressure reduction. The contribution of both macrophage subsets in the modulation of the autonomic activity in cardiovascular regulatory centers is well known [35, [57] [58] [59] [60] [61] . Previous studies reported that Ang II was able to increase blood pressure via the activation of microglia due to a lower BBB permeability in the paraventricular nucleus of the hypothalamus (PVN) in hypertensive animals [57, 62] . We did not observe a decrease of BP after microglia depletion, possibly because microglia were already depleted prior to, not after [62] , Ang IIinduced neurogenic hypertension.
The use of the Cx3Cr1 GFP/WT x Thy1 YFP/0 mouse model may have lead to a reduction in Cx3Cr1 levels. As the insertion of GFP in the Cx3cr1 GFP mouse model was performed at the expense of 390 base pairs in the second exon of the Cx3Cr1 gene, its interaction with its ligand Cx3CL1 is altered as demonstrated when the mouse line was developed [64] . As a result, only heterozygous mice -as in the present study -should be studied to understand the behavior of microglia under healthy and pathological conditions [63] .
In summary, we have shown that short-term memory impairment induced by prolonged Ang II infusion is absent when microglia are depleted using a CSF1R inhibitor. Cognitive effects of PLX5622 treatment were independent of changes in cardiovascular function and blood brain barrier permeability. This novel finding supports the hypothesis that microglia play a critical role in the pathogenesis of hypertension related cognitive impairment. This is a major step towards the development of theranostics targeting the CSF1R (e.g.
[ 11 C]CPPC [65] ). An adequate modulation of microglia density and phenotype may constitute a relevant approach to prevent and/or limit the progression of vascular cognitive impairment.
